VGXI

Company Snapshot

Founded: 1997
Entity Type: Private
Region: U.S.
Headquarter: Texas, U.S.
Key Geographics: U.S.
Corporate Address: 10130 Deison Park Blvd. Conroe, Texas 77303 U.S. Tel. +1-866-901-8494 www.vgxii.com

Company Overview

VGXI Inc. was formed when VGX International acquired VGX Pharmaceuticals in 2007. The company, headquartered in Woodlands, Texas, produces plasmid DNA under GMP for human clinical trials. The company’s cGMP service provides injectable-grade plasmid DNA for clinical trials. The company manufactures DNA plasmids across a range of service levels, including high-purity plasmid DNA preparations for preclinical research, highly documented (HD) DNA plasmids for viral vector production and toxicology studies, and cGMP DNA plasmids for clinical through commercial supply. The company’s plasmid DNA is used in clinical trials and diagnostic reagents and commercially as raw material for GMP viral vector and cell therapy production.

VGXI In Reports

Viral Vector and Plasmid DNA: Technologies and Global Markets

BCC Research Market Analyst says global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028 at a CAGR of 19.7%.

Viral Vector and Plasmid DNA: Technologies and Global Markets

The global viral vector and plasmid DNA technologies market should grow from $500 million in 2019 to over $1.1 billion by 2024 with a compound annual growth rate (CAGR) of 18.0% during the period, 2019-2024.

Company's Business Segments

  • Contract Development and Manufacturing : This segment includes Contract Development, Manufacturing, Production of Plasmid DNA products.

Applications/End User Industries

  • Biopharmaceutical
  • Gene Therapy
  • Healthcare
  • Plasmid DNA
  • DNA Vaccines
  • cGMP Contract Manufacturing
  • Cell Banking
  • HD Plasmid Manufacturing